» Articles » PMID: 3409138

A Clinician's Guide for Conducting Randomized Trials in Individual Patients

Overview
Journal CMAJ
Date 1988 Sep 15
PMID 3409138
Citations 82
Authors
Affiliations
Soon will be listed here.
Abstract

In determining optimal treatment for a patient conventional trials of therapy are susceptible to bias. Large-scale randomized trials can provide only a partial guide and have not been or cannot be carried out for most clinical disorders. However, randomized controlled trials (RCTs) in individual patients (N of 1 RCTs) may in some circumstances provide a solution to this dilemma. In an N of 1 RCT a patient undergoes pairs of treatment periods (one period of each pair with the active drug and one with matched placebo, assigned at random); both the patient and the clinician are blind to allocation, and treatment targets are monitored. N of 1 RCTs are useful for chronic, stable conditions for which the proposed treatment, which has a rapid onset of action and ceases to act soon after it is discontinued, has shown promise in an open trial of therapy. The monitoring of treatment targets usually includes quantitative measurement of the patient's symptoms with the use of simple patient diaries or questionnaires. Pairs of treatment periods are continued until effectiveness is proved or refuted. The cooperation of a pharmacy is required for the preparation of matching placebos and conduct of the trial. Formal statistical analysis may be helpful for interpreting the results. The practical approach presented in this paper allows clinicians to conduct their own N of 1 RCTs.

Citing Articles

A qualitative study on the facilitators and barriers to adopting the N-of-1 trial methodology as part of clinical practice: potential versus implementation challenges.

Wilmont I, Loeffen M, Hoogeboom T Int J Qual Stud Health Well-being. 2024; 19(1):2318810.

PMID: 38417032 PMC: 10903748. DOI: 10.1080/17482631.2024.2318810.


The analysis of continuous data from n-of-1 trials using paired cycles: a simple tutorial.

Senn S Trials. 2024; 25(1):128.

PMID: 38365817 PMC: 10870460. DOI: 10.1186/s13063-024-07964-7.


Personalized Trial Ethics and Institutional Review Board Submissions.

Samuel J, Wootton S Harv Data Sci Rev. 2024; 2022(Spec Iss 3).

PMID: 38283318 PMC: 10813651. DOI: 10.1162/99608f92.2ded0fc5.


Cannabidiol (Epidyolex®) for severe behavioral manifestations in patients with tuberous sclerosis complex, mucopolysaccharidosis type III and fragile X syndrome: protocol for a series of randomized, placebo-controlled N-of-1 trials.

Muller A, den Hollander B, van de Ven P, Roes K, Geertjens L, Bruining H BMC Psychiatry. 2024; 24(1):23.

PMID: 38177999 PMC: 10768432. DOI: 10.1186/s12888-023-05422-3.


N-of-1 Trials, Their Reporting Guidelines, and the Advancement of Open Science Principles.

Porcino A, Vohra S Harv Data Sci Rev. 2023; 4(SI3).

PMID: 38031562 PMC: 10686313. DOI: 10.1162/99608f92.a65a257a.


References
1.
Kirshner B, Guyatt G . A methodological framework for assessing health indices. J Chronic Dis. 1985; 38(1):27-36. DOI: 10.1016/0021-9681(85)90005-0. View

2.
Guyatt G, BERMAN L, Townsend M, Taylor D . Should study subjects see their previous responses?. J Chronic Dis. 1985; 38(12):1003-7. DOI: 10.1016/0021-9681(85)90098-0. View

3.
Haynes R, McKibbon K, Fitzgerald D, Guyatt G, Walker C, Sackett D . How to keep up with the medical literature: I. Why try to keep up and how to get started. Ann Intern Med. 1986; 105(1):149-53. DOI: 10.7326/0003-4819-105-1-149. View

4.
Guyatt G, Bombardier C, Tugwell P . Measuring disease-specific quality of life in clinical trials. CMAJ. 1986; 134(8):889-95. PMC: 1490966. View

5.
McLeod R, Taylor D, Cohen Z, Cullen J . Single-patient randomised clinical trial. Use in determining optimum treatment for patient with inflammation of Kock continent ileostomy reservoir. Lancet. 1986; 1(8483):726-8. DOI: 10.1016/s0140-6736(86)91112-8. View